RxDoctor Payments DataLook up a doctor →

Michael Cronen, DO

Pain Medicine · Louisville, KYNPI 1609854520

Payments from drug & device makers

$10,031in general payments, 2019–2025

Across 505 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Si-bone, Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Amgen$490
  • Biohaven Pharmaceuticals, Inc.$484
  • Collegium Pharmaceutical, Inc.$459
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$1001%
  • Food & beverage$9,90799%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,031 in reported general payments places this provider in the 70th percentile of 90 pain medicine providers in Kentucky.

See all pain medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$374,738
Medicare patients
618
Services billed
11,003

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl55$62,345
Xtampza ErOxycodone Myristate47$30,626
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen899$23,211
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen585$23,168
Gabapentin334$6,310
Morphine Sulfate ErMorphine Sulfate149$6,289
Pregabalin93$4,240
Buprenorphine13$3,850
Oxycodone Hcl125$3,309
Tramadol Hcl185$1,791
Morphine Sulfate31$984
Baclofen43$689
Tizanidine Hcl45$418
Methocarbamol11$230
Meloxicam15$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$459$30,62647 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$197$4,83444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 90 pain medicine providers in Kentucky.

Other pain medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →